An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Necitumumab (Primary) ; Osimertinib (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.
- 08 Dec 2021 Planned End Date changed from 16 Nov 2021 to 16 Nov 2022.
- 18 May 2021 Planned End Date changed from 16 May 2021 to 16 Nov 2021.